Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Moves Real-World Evidence Paradigm Forward With Draft Guidance

Executive Summary

The US agency has followed its public enthusiasm for increasing the use of real-world evidence to support pre-market and post-market device decisions with a draft guidance mapping out a strategy for doing so.


Related Content

Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed